Daily Endocrinology Research Analysis
Analyzed 99 papers and selected 3 impactful papers.
Summary
Genomic analyses expand the biological understanding of polycystic ovary syndrome, linking risk loci to reproductive longevity and cardiometabolic traits. A mechanistic study identifies the adipokine Adissp as a potent insulin-independent regulator of glucose disposal and thermogenesis in white fat. Real-world evidence shows GLP-1 receptor agonists reduce macrovascular and microvascular complications in type 2 diabetes patients with pre-existing diabetic retinopathy.
Research Themes
- Genomic architecture and proteomics in endocrine disorders
- Insulin-independent metabolic signaling and adipokine therapeutics
- Real-world cardiometabolic outcomes with incretin-based therapies
Selected Articles
1. Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome.
This large-scale human genetic study expands PCOS risk loci to 29, links 31 plasma proteins, and highlights associations with later menopause, indicating reproductive longevity biology. Polygenic risk relates to adverse cardiometabolic outcomes with sex-specific contributions of testosterone and BMI, while PCOS susceptibility does not increase childlessness.
Impact: Defines the genomic and proteomic landscape of PCOS at unprecedented scale, refining etiologic hypotheses and risk stratification. Provides mechanistic links between reproductive longevity and cardiometabolic risk.
Clinical Implications: While not immediately practice-changing, the findings inform biomarker discovery and risk stratification, motivate mechanistic studies of hormonal-metabolic axes, and could guide personalized surveillance for cardiometabolic comorbidities in PCOS.
Key Findings
- Expanded PCOS risk loci from 16 to 29 across n=544,513 individuals.
- Identified 31 PCOS-associated plasma proteins, emphasizing metabolic biology.
- Risk loci associated with later age at menopause, implying reproductive longevity biology.
- Polygenic risk score associated with adverse cardiometabolic outcomes, with sex-specific roles of testosterone and BMI.
- No detectable impact of PCOS susceptibility on childlessness, suggesting balanced pleiotropy for fertility.
Methodological Strengths
- Very large sample size with multi-ancestry power enabling robust locus discovery.
- Integration of genomics with proteomics and polygenic risk modeling for multidimensional inference.
Limitations
- Observational genetic associations cannot establish causality for specific pathways.
- Generalizability to underrepresented ancestries and potential cohort heterogeneity may limit translation.
Future Directions: Mendelian randomization and functional studies to pinpoint causal effector genes/pathways; development of proteomic/genetic risk tools; investigation of sex-specific cardiometabolic trajectories in PCOS.
Polycystic ovary syndrome (PCOS) and its underlying features remain poorly understood. In this genetic study (n = 544,513), we expand the number of genetic loci from 16 to 29, and additionally identify 31 associated plasma proteins. Many risk-increasing loci were associated with later age at menopause, underscoring the reproductive longevity related to an increased oocyte number and/or availability across the lifespan. Hormonal regulation in the etiology of this condition, through metabolic and reproductive features, was emphasized. The proteomic analysis highlighted metabolic biology known to be related to PCOS. A polygenic risk score (PRS) was associated with adverse cardiometabolic outcomes, with differing relevance of testosterone and body mass index in women and men. Finally, while oligo-anovulation and anovulatory infertility are features of PCOS, we observed no impact of PCOS susceptibility on childlessness. We suggest that PCOS susceptibility confers balanced pleiotropic influences on fertility in women, and life-long adverse metabolic consequences in both sexes.
2. Adissp activates insulin-independent glucose disposal and energy expenditure in white fat to treat diabetes and cardiometabolic disease.
Adissp is identified as an adipokine that activates insulin-independent Akt signaling in white adipose tissue, normalizing hyperglycemia in T1D and T2D mice and inducing a thermogenic program that reduces body weight and improves cardiometabolic health. It functionally mimics brown fat/cold exposure, revealing a new insulin-independent glucose uptake pathway.
Impact: Reveals a novel, druggable insulin-independent pathway for glucose uptake and energy expenditure with a single adipokine, offering a unifying mechanism to treat diabetes and cardiometabolic disease.
Clinical Implications: If translatable, Adissp or its analogs could complement or substitute insulin-centric therapies, aiding glycemic control in insulinopenic states and addressing obesity-related cardiometabolic risk via thermogenesis.
Key Findings
- Recombinant Adissp sustainably normalizes hyperglycemia in both type 1 and type 2 diabetic mice via insulin-independent Akt signaling.
- Adissp induces a comprehensive thermogenic program in white adipose tissue, reducing body weight and improving cardiometabolic parameters.
- Endogenous Adissp is essential for glucose homeostasis, and Adissp acts as a cold mimetic recapitulating BAT benefits.
- Findings uncover an unanticipated insulin-independent glucose uptake pathway in adipose tissue.
Methodological Strengths
- Multiple in vivo disease models (T1D and T2D mice) demonstrating sustained glycemic normalization.
- Mechanistic dissection of signaling (insulin-independent Akt) with convergent metabolic phenotyping (thermogenesis, weight loss).
Limitations
- Preclinical mouse-focused evidence without human translational data or safety/pharmacokinetics.
- Molecular target context and long-term effects in complex comorbid settings remain to be defined.
Future Directions: Identify receptor/targets and downstream effectors, evaluate pharmacology/toxicology in large animals, and initiate first-in-human studies focusing on insulinopenic diabetes and obesity-related cardiometabolic disease.
Whether a pharmacological strategy can replicate the broad improvement of human cardiometabolic health associated with brown fat (BAT) remains an active area of investigation. Here, we show that adipokine Adissp activates both glucose disposal and energy expenditure within white fat, delivering pleiotropic metabolic benefits. Endogenous Adissp is essential for glucose homeostasis. Administration of recombinant Adissp (rAdissp) protein sustainably normalizes hyperglycemia in type 1 and type 2 diabetic mice by activating insulin-independent Akt signaling. Furthermore, rAdissp robustly induces a comprehensive thermogenic program, which not only reduces body weight but also independently ameliorates a wide range of cardiometabolic diseases. Thus, a single adipokine, Adissp, recapitulates the systemic metabolic benefits of BAT and essentially functions as a cold mimetic. These findings reveal an unanticipated insulin-independent glucose uptake pathway and offer mechanistic insights into the cardiometabolic protection linked to human BAT. Adissp and its analogs represent a promising class of therapeutic agents to concurrently and synergistically treat diabetes and cardiometabolic diseases.
3. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy.
In a large, propensity-matched, retrospective cohort of T2D patients with diabetic retinopathy, GLP-1 receptor agonists were associated with substantial reductions in macrovascular (MI, stroke, HF) and microvascular (AKI, RRT, proliferative DR, RVO, neovascular glaucoma) complications over two years, without increased risk of RAO or NAION.
Impact: Addresses a high-risk population often excluded from trials, demonstrating broad vascular benefits of GLP-1 RAs including retinal outcomes.
Clinical Implications: Supports considering GLP-1 RAs for T2D patients with diabetic retinopathy to reduce systemic and ocular vascular events, informing risk–benefit discussions and care pathways.
Key Findings
- After PSM (n≈30,613 GLP-1 RA users), GLP-1 RAs were associated with lower risks of MI (HR 0.65), ischemic stroke (HR 0.78), HF exacerbations (HR 0.78), and coronary revascularization (HR 0.75).
- Microvascular benefits included reduced AKI (HR 0.68), reduced need for RRT (HR 0.40), and lower risks of proliferative DR (HR 0.78), RVO (HR 0.70), and neovascular glaucoma (HR 0.65).
- No significant association was observed with RAO or NAION over two years.
Methodological Strengths
- Large, real-world population with propensity score matching to balance baseline characteristics.
- Comprehensive assessment of macrovascular and microvascular (ocular and renal) outcomes over two years.
Limitations
- Retrospective observational design limits causal inference and may be subject to residual confounding.
- Medication exposure and clinical management details may vary across sites within the network.
Future Directions: Prospective studies and randomized trials in DR populations to confirm benefits, explore mechanisms, and define optimal sequencing with other retinopathy treatments.
PURPOSE: To evaluate the association of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use on macrovascular and microvascular outcomes in patients with type 2 diabetes (T2D) and diabetic retinopathy (DR)-a high-risk group often excluded from clinical trials. DESIGN: Retrospective, population-based cohort study. PARTICIPANTS: Adults aged ≥18 years with T2D (with hemoglobin A1c of ≥6.5%) and a pre-existing diagnosis of DR from the TriNetX research network database between January 1, 2015, and December 31, 2022. METHODS: The study included 173,216 adults with T2D, all of whom had DR, adjusted for baseline characteristics through propensity score matching (PSM) based on whether the individuals received at least two prescriptions of a GLP-1 RA (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) at least six months apart. MAIN OUTCOME MEASURES: Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident macrovascular and microvascular complications over a two-year follow-up period. RESULTS: After PSM, 30,613 individuals (mean [SD] age, 61.6 [11.4] years; 53.2% were females) were prescribed GLP-1 RAs. Patients on GLP-1 RAs had a decreased risk of myocardial infarctions (MIs; hazard ratio [HR], 0.65; 95% CI, 0.61-0.69), coronary artery revascularization procedures (HR, 0.75; 95% CI, 0.67-0.84), heart failure exacerbations (HR, 0.78; 95% CI, 0.76-0.81), ischemic strokes (HR, 0.78; 95% CI, 0.74-0.83), lower extremity amputations (HR, 0.78; 95% CI, 0.69-0.88), acute kidney injuries (AKI; HR, 0.68; 95% CI, 0.66-0.71), or the need for renal replacement therapy (RRT; HR, 0.40; 95% CI, 0.36-0.43). Fewer individuals also progressed to proliferative diabetic retinopathy (HR, 0.78; 95% CI, 0.71-0.86), experienced retinal vein occlusions (RVOs; HR, 0.70; 95% CI, 0.61-0.80), or developed neovascular glaucoma (HR, 0.65; 95% CI, 0.47-0.89); no association was observed for retinal artery occlusions (RAOs; HR, 0.85; 95% CI, 0.57-1.26) or cases of non-arteritic ischemic optic neuropathy (NAION; HR, 0.88; 95% CI, 0.54-1.44). CONCLUSIONS: In patients with T2D and pre-existing DR, the use of GLP-1 RAs was associated with a reduced risk of major macrovascular and microvascular complications, including those directly affecting the retina. Future studies are needed to assess the extent to which GLP-1 RAs benefit long-term outcomes.